https://www.profitconfidential.com/news/cardinal-health-to-acquire-harvard-drug-group-for-1-115-billion/
Cardinal Health to Acquire Harvard Drug Group for $1.115 Billion
Jing Pan, B.Sc, MA
Profit Confidential
2015-06-05T22:00:30Z
2015-06-08 08:55:38 cardinal healthharvard drug grouppharmaceutical m&amergersCardinal Health announces it’s acquiring the Harvard Drug Group, funding the acquisition with existing cash and new debt.
News
https://www.profitconfidential.com/wp-content/uploads/2015/06/Cardinal-Health-to-Buy-Generics-Distributor.jpg On Friday, June 5, Cardinal Health, Inc. (NYSE/CAH) announced that it would acquire The Harvard Drug Group for $1.115 billion. (Source: Cardinal Health, June 5, 2015.) Cardinal Health is a healthcare services company specializing in the distribution of pharmaceuticals and medical products. It serves more than 60,000 locations. The company also manufactures medical and surgical products. Cardinal Health is headquartered in Dublin, Ohio. The Harvard Drug Group is a distributor of generic pharmaceuticals, over-the-counter medications, and related products. It serves institutional, retail, and alternate care customers. The company is currently owned by Court Square Capital Partners, a private equity firm. Last year, the Harvard Drug Group had revenue of around $450 million. Cardinal health would fund the $1.115 billion acquisition with existing cash and new debt. The transaction would include about 450 employees and two distribution facilities. Upon the announcement, shares of Cardinal Health dropped 1.5% at the market’s open, bouncing back to $87.43 at midday.

Acquisition Good for EPS

According to George Barrett, chairman and CEO of Cardinal Health, the acquisition is in line with the company’s goal of providing the most comprehensive line of products to the widest range of customers. “This acquisition enhances our ability to support retail and institutional customers and further utilizes Red Oak, our joint venture with CVS Health, to source generics.” Cardinal Health is expecting the deal to boost earnings per share (EPS) by more than $0.15 per share in fiscal 2016, and more than $0.20 per share in fiscal 2017. The deal would generate even greater growth in EPS in future years. Buying companies is not new to Cardinal Health. Last month, Johnson & Johnson (NYSE/JNJ) officially announced that it accepted Cardinal Health’s offer to acquire its heart-product business, Cordis, for $1.944 billion. That deal would be all cash and is expected to close by the end of this year.

Cardinal Health to Acquire Harvard Drug Group for $1.115 Billion

By Jing Pan, B.Sc, MA Published : June 5, 2015

On Friday, June 5, Cardinal Health, Inc. (NYSE/CAH) announced that it would acquire The Harvard Drug Group for $1.115 billion. (Source: Cardinal Health, June 5, 2015.) Cardinal Health is a healthcare services company specializing in the distribution of pharmaceuticals and medical products. It serves more than 60,000 locations. The company also manufactures medical and surgical products. Cardinal Health is headquartered in Dublin, Ohio. The Harvard Drug Group is a distributor of generic pharmaceuticals, over-the-counter medications, and related products. It serves institutional, retail, and alternate care customers. The company is currently owned by Court Square Capital Partners, a private equity firm. Last year, the Harvard Drug Group had revenue of around $450 million. Cardinal health would fund the $1.115 billion acquisition with existing cash and new debt. The transaction would include about 450 employees and two distribution facilities. Upon the announcement, shares of Cardinal Health dropped 1.5% at the market’s open, bouncing back to $87.43 at midday.

Acquisition Good for EPS

According to George Barrett, chairman and CEO of Cardinal Health, the acquisition is in line with the company’s goal of providing the most comprehensive line of products to the widest range of customers. “This acquisition enhances our ability to support retail and institutional customers and further utilizes Red Oak, our joint venture with CVS Health, to source generics.” Cardinal Health is expecting the deal to boost earnings per share (EPS) by more than $0.15 per share in fiscal 2016, and more than $0.20 per share in fiscal 2017. The deal would generate even greater growth in EPS in future years. Buying companies is not new to Cardinal Health. Last month, Johnson & Johnson (NYSE/JNJ) officially announced that it accepted Cardinal Health’s offer to acquire its heart-product business, Cordis, for $1.944 billion. That deal would be all cash and is expected to close by the end of this year.

Dear Reader: There is no magic formula to getting rich. Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis. We are 100% independent in that we are not affiliated with any bank or brokerage house. Information contained herein, while believed to be correct, is not guaranteed as accurate. Warning: Investing often involves high risks and you can lose a lot of money. Please do not invest with money you cannot afford to lose. The opinions in this content are just that, opinions of the authors. We are a publishing company and the opinions, comments, stories, reports, advertisements and articles we publish are for informational and educational purposes only; nothing herein should be considered personalized investment advice. Before you make any investment, check with your investment professional (advisor). We urge our readers to review the financial statements and prospectus of any company they are interested in. We are not responsible for any damages or losses arising from the use of any information herein. Past performance is not a guarantee of future results. All registered trademarks are the property of their respective owners.